Literature DB >> 14508821

The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06.

Melvin Deutsch1, Stephanie R Land, Mirsada Begovic, H Samuel Wieand, Norman Wolmark, Bernard Fisher.   

Abstract

BACKGROUND: In the current study, the authors compared the incidence of subsequent primary lung carcinoma in patients with breast carcinoma who received radiotherapy as part of their treatment and in those patients who did not. The patients were participants in two large National Surgical Adjuvant Breast and Bowel Project (NSABP) breast carcinoma trials, B-04 and B-06, which prospectively randomized women to either undergo surgery alone or to undergo surgery and postoperative radiotherapy.
METHODS: The NSABP trial B-04 (1971-1974) randomized patients to undergo radical mastectomy versus total (simple) mastectomy and radiotherapy to the chest wall, axilla, and supraclavicular and internal mammary lymph node areas. For patients with a clinically uninvolved axilla, there was a third randomization arm: total mastectomy without radiotherapy. The B-06 trial (1976-1984) randomized patients between those undergoing total mastectomy versus lumpectomy versus those undergoing lumpectomy and breast irradiation, with all patients undergoing an axillary lymph node dissection. The records of all patients who developed a recurrence in the lung or a new primary lung tumor were reviewed to determine the incidence and laterality of confirmed and probable primary lung carcinoma.
RESULTS: For the 1665 evaluable patients on the NSABP B-04 trial (mean follow-up of 21.4 years), there was a total of 23 subsequent confirmed and probable ipsilateral or contralateral primary lung carcinomas. In those patients who had received comprehensive postmastectomy radiotherapy, there was a statistically significant increase in the incidence of these new primary tumors (P = 0.029). With regard to the development of confirmed new primary ipsilateral lung carcinoma alone, the incidence was statistically significantly increased (P = 0.013) in those patients who had received radiotherapy as part of their treatment, and when confirmed and probable ipsilateral lung carcinomas were analyzed, there was a strong trend toward a statistically significant increase in those patients who had received radiotherapy (P = 0.066). For the 1850 evaluable patients on the NSABP trial B-06 (mean follow-up of 19.0 years), there was a total of 30 second primary lung carcinomas but no increase in either ipsilateral or contralateral primary tumors of the lung in those patients who had received radiotherapy.
CONCLUSIONS: Extensive postmastectomy irradiation of the chest wall and regional lymphatic node areas, with consequent exposure of a greater volume of lung to higher doses as administered in the NSABP B-04 trial compared with postlumpectomy breast irradiation in the NSABP B-06 trial, was associated with an increased incidence of subsequent primary lung tumors, both ipsilateral and contralateral. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11655

Entities:  

Mesh:

Year:  2003        PMID: 14508821     DOI: 10.1002/cncr.11655

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Second malignancies in high‑dose areas of previous tumor radiotherapy.

Authors:  Birgitta Welte; Peter Suhr; Dirk Bottke; Detlef Bartkowiak; Wolfgang Dörr; Klaus Rüdiger Trott; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

Review 2.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

3.  Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation.

Authors:  Melissa Pilewskie; Cristina Olcese; Anne Eaton; Sujata Patil; Elizabeth Morris; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2014-01-03       Impact factor: 5.344

Review 4.  Secondary malignancies across the age spectrum.

Authors:  Andrea K Ng; Lisa B Kenney; Ethel S Gilbert; Lois B Travis
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

5.  [No increased rate of secondary malignancies after pelvic radiotherapy].

Authors:  Karen Huber; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2015-04       Impact factor: 3.621

6.  Predicting the risk of secondary lung malignancies associated with whole-breast radiation therapy.

Authors:  John Ng; Igor Shuryak; Yanguang Xu; K S Clifford Chao; David J Brenner; Ryan J Burri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-13       Impact factor: 7.038

Review 7.  Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.

Authors:  Agnès Tallet; Eric Lambaudie; Monique Cohen; Mathieu Minsat; Marie Bannier; Michel Resbeut; Gilles Houvenaeghel
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 8.  Epidemiology of lung cancer.

Authors:  Carole A Ridge; Aoife M McErlean; Michelle S Ginsberg
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

9.  Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.

Authors:  Min Yi; Janice N Cormier; Yan Xing; Sharon Hermes Giordano; Christy Chai; Funda Meric-Bernstam; Georges Vlastos; Henry M Kuerer; Nadeem Q Mirza; Thomas A Buchholz; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2012-12-06       Impact factor: 5.344

10.  Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.

Authors:  A Berrington de Gonzalez; R E Curtis; E Gilbert; C D Berg; S A Smith; M Stovall; E Ron
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.